Bayer Healthcare has launched its new anti-clotting drug Xarelto (rivaroxaban) in China following SFDA approval. As Liam Condon, Managing Director of Bayer HealthCare China said at last week’s ChinaBio® Partnering Forum, the fact that Xarelto was approved in China before the US shows Bayer’s commitment to bringing innovative drugs to China simultaneously with other major world markets. Xarelto is an oral medication, taken once daily, that was approved for the relatively narrow indication of preventing deep vein thrombosis in patients who undergo knee or hip replacement surgery. More details...

Stock Symbol: (Xetra: BAYG.DE)